{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T05:40:13Z","timestamp":1789191613614,"version":"build-2803163510"},"reference-count":40,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100007083","name":"Orion Farmos Research Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007083","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003125","name":"Finnish Cultural Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003125","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1016\/j.ejca.2012.09.030","type":"journal-article","created":{"date-parts":[[2012,10,15]],"date-time":"2012-10-15T17:46:23Z","timestamp":1350323183000},"page":"938-945","source":"Crossref","is-referenced-by-count":64,"title":["Use of aspirin, but not other non-steroidal anti-inflammatory drugs is associated with decreased prostate cancer risk at the population level"],"prefix":"10.1016","volume":"49","author":[{"given":"Thea","family":"Veitonm\u00e4ki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teuvo L.J.","family":"Tammela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anssi","family":"Auvinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teemu J.","family":"Murtola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ejca.2012.09.030_b0005","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.ejca.2009.12.014","article-title":"Estimates of cancer incidence and mortality in Europe in 2008","volume":"46","author":"Ferlay","year":"2010","journal-title":"Eur J Cancer"},{"issue":"17","key":"10.1016\/j.ejca.2012.09.030_b0010","doi-asserted-by":"crossref","first-page":"3040","DOI":"10.1016\/j.ejca.2010.09.013","article-title":"Prostate cancer incidence and mortality trends in 37 European countries: an overview","volume":"46","author":"Bray","year":"2010","journal-title":"Eur J Cancer"},{"issue":"5 Suppl.","key":"10.1016\/j.ejca.2012.09.030_b0015","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.urology.2009.03.001","article-title":"Understanding the epidemiology, natural history, and key pathways involved in prostate cancer","volume":"73","author":"Crawford","year":"2009","journal-title":"Urology"},{"issue":"4","key":"10.1016\/j.ejca.2012.09.030_b0020","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/pros.2990170409","article-title":"Family history and the risk of prostate cancer","volume":"17","author":"Steinberg","year":"1990","journal-title":"Prostate"},{"key":"10.1016\/j.ejca.2012.09.030_b0025","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/nrc2090","article-title":"Inflammation in prostate carcinogenesis","volume":"7","author":"De Marzo","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ejca.2012.09.030_b0030","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0304-3835(02)00524-4","article-title":"Cyclooxygenase-2 and prostate carcinogenesis","volume":"191","author":"Hussain","year":"2003","journal-title":"Cancer Lett"},{"issue":"1","key":"10.1016\/j.ejca.2012.09.030_b0035","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/(SICI)1097-0045(20000101)42:1<73::AID-PROS9>3.0.CO;2-G","article-title":"Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma","volume":"42","author":"Gupta","year":"2000","journal-title":"Prostate"},{"issue":"3","key":"10.1016\/j.ejca.2012.09.030_b0040","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/1097-0142(20000801)89:3<589::AID-CNCR14>3.0.CO;2-C","article-title":"Expression of cyclooxygenase-2 in prostate carcinoma","volume":"89","author":"Yoshimura","year":"2000","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.ejca.2012.09.030_b0045","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/S1470-2045(07)70280-2","article-title":"T COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92-02 trial","volume":"8","author":"Khor","year":"2007","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2012.09.030_b0050","doi-asserted-by":"crossref","first-page":"376","DOI":"10.7326\/0003-4819-146-5-200703060-00010","article-title":"US Preventive Services Task Force. Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the US Preventive Services Task Force","volume":"146","author":"Rostom","year":"2007","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.ejca.2012.09.030_b0055","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1053\/gast.2003.50008","article-title":"Protective association of aspirin\/NSAIDs and esophageal cancer: a systematic review and meta-analysis","volume":"124","author":"Corley","year":"2003","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.ejca.2012.09.030_b0060","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1097\/CEJ.0b013e328339648c","article-title":"Meta-analysis on the relationship between nonsteroidal anti-inflammatory drug use and gastric cancer","volume":"19","author":"Tian","year":"2010","journal-title":"Eur J Cancer Prev"},{"issue":"7","key":"10.1016\/j.ejca.2012.09.030_b0065","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1093\/aje\/kwq437","article-title":"Nonsteroidal antiinflammatory drugs and bladder cancer: a pooled analysis","volume":"173","author":"Daugherty","year":"2011","journal-title":"Am J Epidemiol"},{"issue":"8","key":"10.1016\/j.ejca.2012.09.030_b0070","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1002\/pros.21297","article-title":"Regression of prostate tumors upon combination of hormone ablation therapy and celecoxib in vivo","volume":"71","author":"Abedinpour","year":"2011","journal-title":"Prostate"},{"issue":"7","key":"10.1016\/j.ejca.2012.09.030_b0075","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1002\/ijc.25186","article-title":"Use of nonsteroidal anti-inflammatory drugs and prostate cancer risk: a meta-analysis","volume":"127","author":"Mahmud","year":"2010","journal-title":"Int J Cancer"},{"issue":"4","key":"10.1016\/j.ejca.2012.09.030_b0080","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3109\/02841869409098430","article-title":"Data quality and quality control of a population-based cancer registry","volume":"33","author":"Teppo","year":"1994","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ejca.2012.09.030_b0085","unstructured":"Martikainen J, Rajaniemi S. Drug reimbursement systems in EU member states, Iceland and Norway. Helsinki, Finland: The Social Insurance Institution, Finland, Social security and health reports 54; 2002. Available from: <http:\/\/www.kela.fi\/in\/internet\/english.nsf\/NET\/100203115310PN>."},{"issue":"4","key":"10.1016\/j.ejca.2012.09.030_b0090","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1002\/sim.2580","article-title":"A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study","volume":"26","author":"Austin","year":"2007","journal-title":"Stat Med"},{"key":"10.1016\/j.ejca.2012.09.030_b0095","unstructured":"World Health Organization. ATC\/DDD index database. <http:\/\/www.whocc.no\/atcddd\/indexdatabase\/index.php?query=A10>."},{"key":"10.1016\/j.ejca.2012.09.030_b0100","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0002-9343(98)00091-6","article-title":"Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs","volume":"104","author":"Cryer","year":"1998","journal-title":"Am J Med"},{"issue":"5","key":"10.1016\/j.ejca.2012.09.030_b0105","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1358\/mf.2000.22.5.796648","article-title":"Cyclooxygenase isoenzymes and newer therapeutic potential for selective COX-2 inhibitors","volume":"22","author":"Kulkarni","year":"2000","journal-title":"Methods Find Exp Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.ejca.2012.09.030_b0110","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1093\/aje\/kwq175","article-title":"Use of aspirin and other nonsteroidal anti-inflammatory medications in relation to prostate cancer risk","volume":"172","author":"Salinas","year":"2010","journal-title":"Am J Epidemiol"},{"issue":"7","key":"10.1016\/j.ejca.2012.09.030_b0115","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1158\/1055-9965.EPI-11-0210","article-title":"A large cohort study of long-term acetaminophen use and prostate cancer incidence","volume":"20","author":"Jacobs","year":"2011","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"6","key":"10.1016\/j.ejca.2012.09.030_b0120","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1002\/ijc.25465","article-title":"Associations of aspirin, nonsteroidal anti-inflammatory drug and paracetamol use with PSA-detected prostate cancer: findings from a large, population-based, case\u2013control study (the ProtecT study)","volume":"128","author":"Murad","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2012.09.030_b0125","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1038\/sj.bjc.6600945","article-title":"Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study","volume":"88","author":"S\u00f8rensen","year":"2003","journal-title":"Br J Cancer"},{"issue":"12","key":"10.1016\/j.ejca.2012.09.030_b0130","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1158\/1055-9965.EPI-10-0942","article-title":"Nonsteroidal anti-inflammatory drugs and prostate cancer risk in the VITamins and Lifestyle (VITAL) cohort","volume":"19","author":"Brasky","year":"2010","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"10 Pt. 1","key":"10.1016\/j.ejca.2012.09.030_b0135","first-page":"1108","article-title":"Aspirin use in relation to risk of prostate cancer","volume":"11","author":"Leitzmann","year":"2002","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"7250","key":"10.1016\/j.ejca.2012.09.030_b0140","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1136\/bmj.320.7250.1642","article-title":"Effect of anti-inflammatory drugs on overall risk of common cancer: case\u2013control study in general practice research database","volume":"320","author":"Langman","year":"2000","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.ejca.2012.09.030_b0145","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bjc.2011.252","article-title":"Exposure to cyclooxygenase-2 inhibitors and risk of cancer: nested case\u2013control studies","volume":"105","author":"Vinogradova","year":"2011","journal-title":"Br J Cancer"},{"issue":"Suppl. 2","key":"10.1016\/j.ejca.2012.09.030_b0150","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1464-410X.2003.04407.x","article-title":"Contamination by opportunistic screening in the European Randomized Study of Prostate Cancer Screening","volume":"92","author":"Ciatto","year":"2003","journal-title":"BJU Int"},{"issue":"9","key":"10.1016\/j.ejca.2012.09.030_b0155","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/pros.20951","article-title":"Effects of simvastatin, acetylsalicylic acid and rosiglitazone on proliferation of normal and cancerous prostate epithelial cells at therapeutic concentrations","volume":"69","author":"Murtola","year":"2009","journal-title":"Prostate"},{"issue":"2","key":"10.1016\/j.ejca.2012.09.030_b0160","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/nrurol.2011.219","article-title":"Aspirin and urologic cancer risk: an update","volume":"9","author":"Bosetti","year":"2012","journal-title":"Nat Rev Urol"},{"issue":"7","key":"10.1016\/j.ejca.2012.09.030_b0165","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s10552-011-9769-9","article-title":"Non-steroidal anti-inflammatory drugs (NSAIDs) and breast cancer risk: differences by molecular subtype","volume":"22","author":"Brasky","year":"2011","journal-title":"Cancer Causes Control"},{"issue":"1","key":"10.1016\/j.ejca.2012.09.030_b0170","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0165-6147(96)01017-6","article-title":"A classification of NSAIDs according to the relative inhibition of cyclooxygenase isoenzymes Review","volume":"18","author":"Fr\u00f6lich","year":"1997","journal-title":"Trends Pharmacol Sci"},{"issue":"3","key":"10.1016\/j.ejca.2012.09.030_b0175","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/pros.10152","article-title":"Cyclooxygenase-2 promotes prostate cancer progression","volume":"53","author":"Fujita","year":"2002","journal-title":"Prostate"},{"issue":"25","key":"10.1016\/j.ejca.2012.09.030_b0180","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1200\/JCO.2009.27.9406","article-title":"Impact of common medications on serum total prostate-specific antigen levels: analysis of the National Health and Nutrition Examination Survey","volume":"28","author":"Chang","year":"2010","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2012.09.030_b0185","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1002\/pds.1454","article-title":"Using prescription claims data for drugs available over-the-counter (OTC)","volume":"16","author":"Yood","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"10.1016\/j.ejca.2012.09.030_b0190","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.eururo.2011.03.055","article-title":"The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation","volume":"60","author":"Nunzio","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.ejca.2012.09.030_b0195","unstructured":"Statistics Finland. Finland in figures: population structure. <http:\/\/www.stat.fi\/til\/vaerak\/index.html>."},{"issue":"2","key":"10.1016\/j.ejca.2012.09.030_b0200","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1056\/NEJM200007133430201","article-title":"Environmental and heritable factors in the causation of cancer \u2013 analyses of cohorts of twins from Sweden, Denmark, and Finland","volume":"343","author":"Lichtenstein","year":"2000","journal-title":"N Engl J Med"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804912007812?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804912007812?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T05:53:50Z","timestamp":1588830830000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804912007812"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["S0959804912007812"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2012.09.030","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2013,3]]}}}